Early Psychomotor Development and Growth Hormone Therapy in Children with Prader-Willi Syndrome: a Review

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 2023 Nov 21

PMID 37987848

Authors

Yu-Yu Jin

Fei-Hong Luo

Affiliations

Soon will be listed here.

Abstract

Prader-Willi syndrome (PWS) is a rare genetic disorder caused by the loss of imprinted gene expression on the paternal chromosome 15q11-q13. PWS is characterized by varying degrees of early psychomotor developmental deficits, primarily in cognition, language, and motor development. This review summarizes the early mental cognitive development, language development, and motor development in patients with PWS, compares the correlation of genotype with phenotype, and provides an update regarding the effects and concerns related to potential main side effects of treatment with recombinant human growth hormone on early psycho-cognitive and motor function development along with the linear growth and body composition of children with PWS.Conclusion: Early psychomotor development is strongly correlated with the prognosis of patients with PWS; moreover, current studies support that the initiation of interventions at an early age can exert significant beneficial effects on enhancing the cognitive and linguistic development of patients with PWS and allow them to "catch up" with motor development. What is Known: • Prader-Willi syndrome is a rare genetic disorder characterized by multisystem damage, and children with Prader-Willi syndrome are typically characterized by early developmental delays, specifically in the areas of cognitive and motor development. • Recombinant human growth hormone therapy is the only medical treatment approved for Prader-Willi syndrome. What is New: • Extensive presentation of psycho-cognitive and motor development features and genotype-phenotype correlation in children with Prader-Willi syndrome. • The effects of growth hormone on early psychomotor development in children with Prader-Willi syndrome were thoroughly reviewed, including their short- and long-term outcomes and any associated adverse effects.

Citing Articles

The Effects of Growth Hormone Treatment Beyond Growth Promotion in Patients with Genetic Syndromes: A Systematic Review of the Literature.

Kucharska A, Witkowska-Sedek E, Erazmus M, Artemniak-Wojtowicz D, Krajewska M, Pyrzak B Int J Mol Sci. 2024; 25(18).

PMID: 39337654 PMC: 11432634. DOI: 10.3390/ijms251810169.

References

Cassidy S, Schwartz S, Miller J, Driscoll D . Prader-Willi syndrome. Genet Med. 2012; 14(1):10-26. DOI: 10.1038/gim.0b013e31822bead0. View

Mackay J, McCallum Z, Ambler G, Vora K, Nixon G, Bergman P . Requirements for improving health and well-being of children with Prader-Willi syndrome and their families. J Paediatr Child Health. 2019; 55(9):1029-1037. PMC: 6852695. DOI: 10.1111/jpc.14546. View

Yang-Li D, Fei-Hong L, Hui-Wen Z, Ming-Sheng M, Xiao-Ping L, Li L . Recommendations for the diagnosis and management of childhood Prader-Willi syndrome in China. Orphanet J Rare Dis. 2022; 17(1):221. PMC: 9195308. DOI: 10.1186/s13023-022-02302-z. View

Aycan Z, Bas V . Prader-Willi syndrome and growth hormone deficiency. J Clin Res Pediatr Endocrinol. 2014; 6(2):62-7. PMC: 4141577. DOI: 10.4274/Jcrpe.1228. View

Grootjen L, Trueba-Timmermans D, Damen L, Mahabier E, Kerkhof G, Hokken-Koelega A . Long-Term Growth Hormone Treatment of Children with PWS: The Earlier the Start, the Better the Outcomes?. J Clin Med. 2022; 11(9). PMC: 9105093. DOI: 10.3390/jcm11092496. View

Deal C, Tony M, Hoybye C, Allen D, Tauber M, Christiansen J . GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013; 98(6):E1072-87. PMC: 3789886. DOI: 10.1210/jc.2012-3888. View

Reus L, van Vlimmeren L, Staal J, Otten B, Nijhuis-van Der Sanden M . The effect of growth hormone treatment or physical training on motor performance in Prader-Willi syndrome: a systematic review. Neurosci Biobehav Rev. 2012; 36(8):1817-38. DOI: 10.1016/j.neubiorev.2012.05.005. View

Ayet-Roger A, Joga-Elvira L, Caixas A, Corripio R . Cognitive and Adaptive Effects of Early Growth Hormone Treatment in Prader-Willi Syndrome Patients: A Cohort Study. J Clin Med. 2022; 11(6). PMC: 8955812. DOI: 10.3390/jcm11061592. View

Carrel A, Myers S, Whitman B, Allen D . Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study. J Pediatr. 1999; 134(2):215-21. DOI: 10.1016/s0022-3476(99)70418-x. View

10.

Donze S, Damen L, Mahabier E, Hokken-Koelega A . Improved Mental and Motor Development During 3 Years of GH Treatment in Very Young Children With Prader-Willi Syndrome. J Clin Endocrinol Metab. 2018; 103(10):3714-3719. DOI: 10.1210/jc.2018-00687. View

11.

Shu S, Chien S, Wu Y, Tsai P, Yih J . Anthropometric and intellectual evaluation of individuals with Prader-Willi syndrome. J Formos Med Assoc. 2007; 106(6):509-12. DOI: 10.1016/S0929-6646(09)60303-X. View

12.

Chen C, Chen C, Hou J, Hsu H, Chung C, Chou S . Developmental profiles and mentality in preschool children with Prader-Willi syndrome: a preliminary study. Chang Gung Med J. 2010; 33(4):436-42. View

13.

Copet P, Jauregi J, Laurier V, Ehlinger V, Arnaud C, Cobo A . Cognitive profile in a large French cohort of adults with Prader-Willi syndrome: differences between genotypes. J Intellect Disabil Res. 2010; 54(3):204-15. DOI: 10.1111/j.1365-2788.2010.01251.x. View

14.

Dimitropoulos A, Ferranti A, Lemler M . Expressive and receptive language in Prader-Willi syndrome: report on genetic subtype differences. J Commun Disord. 2013; 46(2):193-201. DOI: 10.1016/j.jcomdis.2012.12.001. View

15.

Dykens E, Hodapp R, Walsh K, Nash L . Profiles, correlates, and trajectories of intelligence in Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry. 1992; 31(6):1125-30. DOI: 10.1097/00004583-199211000-00022. View

16.

Jauregi J, Arias C, Vegas O, Alen F, Martinez S, Copet P . A neuropsychological assessment of frontal cognitive functions in Prader-Willi syndrome. J Intellect Disabil Res. 2007; 51(Pt 5):350-65. DOI: 10.1111/j.1365-2788.2006.00883.x. View

17.

Stauder J, Brinkman M, Curfs L . Multi-modal P3 deflation of event-related brain activity in Prader-Willi syndrome. Neurosci Lett. 2002; 327(2):99-102. DOI: 10.1016/s0304-3940(02)00377-4. View

18.

Ding F, Li H, Zhang S, Solomon N, Camper S, Cohen P . SnoRNA Snord116 (Pwcr1/MBII-85) deletion causes growth deficiency and hyperphagia in mice. PLoS One. 2008; 3(3):e1709. PMC: 2248623. DOI: 10.1371/journal.pone.0001709. View

19.

Whittington J, Holland A . Cognition in people with Prader-Willi syndrome: Insights into genetic influences on cognitive and social development. Neurosci Biobehav Rev. 2016; 72:153-167. DOI: 10.1016/j.neubiorev.2016.09.013. View

20.

Verdine B, Troseth G, Hodapp R, Dykens E . Strategies and correlates of jigsaw puzzle and visuospatial performance by persons with Prader-Willi syndrome. Am J Ment Retard. 2008; 113(5):343-55. DOI: 10.1352/2008.113:342-355. View